Nymox reports positive data for benign prostatic hyperplasia drug

By Elaine Rigoli

Tampa, Fla., May 16 - Nymox Pharmaceutical Corp. announced long-term efficacy results from the open-label phase 1/2 testing of NX-1207, the company's investigational new drug for benign prostatic hyperplasia (BPH).

The new data indicates that at 29 to 34 months after initial treatment, there was highly significant symptomatic improvement, according to a news release.

Comparison to a control group showed that NX-1207 efficacy results reached statistical significance.

Patients in the trial of NX-1207 who were available for follow-up were administered AUA Symptom Score evaluations after periods of 29 to 34 months post treatment. The mean AUA score in patients treated with NX-1207 showed a 6.9 point greater improvement compared to controls. This reached statistical significance and exceeded results from the initial 30-day study of NX-1207 previously reported.

Nymox said BPH afflicts about half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream and other problems.

Nymox is a biopharmaceutical company specializing in the research and development of therapeutics and diagnostics for the aging population with offices located in St. Laurent, Quebec, and Hasbrouck Heights, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.